Response: Still a need for more robust evidence that FLT3/ITD status should influence the decision to proceed to transplantation in AML patients [4]

Blood

Volumn 109, Issue 5, 2007, Pages 2265-

  Gale, Rosemary E ^a   Hills, Robert ^b   Wheatley, Keith ^b   Burnett, Alan K ^b   Linch, David C ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND;

ACUTE GRANULOCYTIC LEUKEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CELL HETEROGENEITY; CONFIDENCE INTERVAL; HUMAN; LETTER; MEDICAL DECISION MAKING; PRIORITY JOURNAL; TREATMENT INDICATION;

EID: 33847403646     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-10-053983     Document Type: Letter

References (1)

1. Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukaemia (AML): an analysis of 1135 patients, excluding promyelocytic leukaemia, from the UK MRC AML10 and 12 trials. Blood. 2005;106:3658-3665.